Artivion, Inc. (NYSE:AORT) Shares Acquired by Calamos Advisors LLC

Calamos Advisors LLC lifted its holdings in Artivion, Inc. (NYSE:AORT - Free Report) by 113.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 63,029 shares of the company's stock after purchasing an additional 33,541 shares during the period. Calamos Advisors LLC owned about 0.15% of Artivion worth $1,802,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its holdings in shares of Artivion by 3.2% in the second quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company's stock worth $392,000 after buying an additional 481 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Artivion by 21.8% in the fourth quarter. GAMMA Investing LLC now owns 2,772 shares of the company's stock worth $79,000 after acquiring an additional 497 shares during the period. Intech Investment Management LLC increased its stake in shares of Artivion by 6.6% in the third quarter. Intech Investment Management LLC now owns 10,530 shares of the company's stock worth $280,000 after acquiring an additional 653 shares during the period. Quarry LP increased its stake in shares of Artivion by 210.8% in the third quarter. Quarry LP now owns 1,209 shares of the company's stock worth $32,000 after acquiring an additional 820 shares during the period. Finally, KBC Group NV increased its stake in shares of Artivion by 80.4% in the fourth quarter. KBC Group NV now owns 2,813 shares of the company's stock worth $80,000 after acquiring an additional 1,254 shares during the period. Hedge funds and other institutional investors own 86.37% of the company's stock.

Artivion Stock Performance

AORT stock traded down $0.71 during midday trading on Friday, hitting $30.56. 356,441 shares of the stock traded hands, compared to its average volume of 342,828. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The firm has a market cap of $1.28 billion, a P/E ratio of -1,528.00 and a beta of 1.75. Artivion, Inc. has a 1-year low of $16.50 and a 1-year high of $32.33. The stock's fifty day simple moving average is $29.72 and its 200-day simple moving average is $27.58.

Insider Buying and Selling at Artivion

In other news, VP Andrew M. Green sold 7,618 shares of the firm's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total value of $228,540.00. Following the transaction, the vice president now directly owns 33,503 shares of the company's stock, valued at approximately $1,005,090. This trade represents a 18.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CAO Amy Horton sold 4,329 shares of the firm's stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $29.66, for a total transaction of $128,398.14. Following the completion of the transaction, the chief accounting officer now directly owns 135,660 shares in the company, valued at approximately $4,023,675.60. This represents a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 20,017 shares of company stock valued at $600,007 over the last ninety days. Corporate insiders own 8.10% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on AORT. Needham & Company LLC reiterated a "buy" rating and issued a $34.00 price objective on shares of Artivion in a research note on Tuesday, January 28th. Oppenheimer increased their price objective on shares of Artivion from $30.00 to $32.00 and gave the stock an "outperform" rating in a research note on Friday, November 8th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $31.80.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.